Hypokalemia — Causes and Management

Potassium Distribution and Cellular Mechanisms

Molecular Basis of Hypokalemia-Induced Arrhythmias

Three Fundamental Mechanisms of Hypokalemia

1. 1.Transcellular Shift (Pseudohypokalemia): Movement of potassium from extracellular to intracellular compartment without change in total body potassium. Insulin stimulation causes GLUT4 translocation and coordinated K+ uptake; β2-adrenergic agonists (albuterol, epinephrine) activate the pump; alkalemia promotes H+ efflux from cells in exchange for K+ influx; and hypothermia may paradoxically cause cellular K+ uptake. These conditions do not represent true total body depletion and may not require aggressive replacement. Conversely, acidemia promotes K+ efflux as cells exchange intracellular K+ for extracellular H+, elevating serum potassium despite total body depletion.

1. 1.Renal Potassium Wasting: Excessive urinary potassium excretion occurs through mechanisms in the collecting duct. Primary hyperaldosteronism (Conn's syndrome) and secondary hyperaldosteronism (volume depletion, congestive heart failure, cirrhosis with ascites) increase expression of epithelial sodium channels (ENaC) and the ROMK (renal outer medullary potassium) channel in principal cells, enhancing sodium reabsorption and potassium secretion through increased electrical gradient. Diuretics (loop and thiazide diuretics) increase sodium delivery to the collecting duct and promote volume contraction, triggering secondary hyperaldosteronism. Renal tubular acidosis (particularly type 1 and type 2 RTA) causes hypokalemia through enhanced distal acid secretion; in RTA type 1 (distal), H+ secretion competes with K+ for the H+-ATPase pump, paradoxically promoting K+ wasting despite systemic acidosis. Amphotericin B causes direct toxicity to the collecting duct, enhancing potassium secretion and often producing concurrent metabolic acidosis. Hypomagnesemia (very common, occurring in 50% of hypokalemic patients) perpetuates renal potassium wasting by increasing ROMK channel activity; this is critical clinically because hypokalemia cannot be corrected until magnesium is repleted.

1. 1.Gastrointestinal and Extrarenal Losses: The gastrointestinal tract normally secretes 5–10 mEq of potassium daily in stool, but diarrhea (particularly chronic diarrhea from inflammatory bowel disease, infectious colitis, or laxative abuse) can increase fecal potassium losses to 100–200 mEq/day. Villous adenoma of the colon secretes potassium-rich mucus, causing severe hypokalemia accompanied by refractory metabolic acidosis. Vomiting causes hypokalemia through dual mechanisms: direct potassium loss in gastric fluid (containing ~10 mEq/L potassium) and contraction alkalosis with secondary hyperaldosteronism from volume depletion. Small bowel and pancreatic fistulas represent substantial potassium losses (15–40 mEq/L in fistula fluid).

Genetic and Pharmacological Modifiers

Diuretic Use (Most Common Cause)

Gastrointestinal Losses

Renal Tubular Dysfunction

Primary and Secondary Hyperaldosteronism

Hypokalemia-Inducing Medications

• Amphotericin B: Polyene antibiotic causing direct tubular toxicity; induces both hypokalemia and metabolic acidosis (Type 1 RTA pattern); lipid formulations (liposomal amphotericin B) cause less electrolyte wasting than conventional formulation
• Cisplatin and other chemotherapy: Magnesium wasting and direct tubular injury
• Corticosteroids: Aldosterone-like effects; methylprednisolone and dexamethasone are higher risk than hydrocortisone due to mineralocorticoid activity
• Toluene toxicity ("glue sniffing"): Blocks distal potassium secretion but causes severe metabolic acidosis; hypokalemia may be masked initially
• Theophylline and β2-agonists (albuterol, terbutaline): Transcellular shift through β2-receptor stimulation
• Insulin: Shifts potassium intracellularly; important in diabetic ketoacidosis management
• Licorice: Mineralocorticoid excess through inhibition of 11β-hydroxysteroid dehydrogenase

Genetic Disorders

• Familial Hypokalemic Periodic Paralysis: Episodic attacks triggered by carbohydrate loading, rest after exercise, or cold; caused by mutations in CACNA1S (60% of cases) or SCN4A (20%); characterized by paralysis with serum K+ often <2.0 mEq/L
• Gitelman Syndrome: Autosomal recessive; chronic hypokalemia, hypomagnesemia, hypocalciuria, and metabolic alkalosis; mutation in SLC12A3
• Bartter Syndrome: Autosomal recessive; neonatal or infantile onset with severe hypokalemia, metabolic alkalosis, hyperreninemia; mutations in genes encoding loop of Henle transporters

Other Causes

• Leukemia (particularly acute myeloid leukemia with high leukemic burden): Leukemic blasts take up potassium, causing pseudohypokalemia or true hypokalemia
• Insulin administration and glucose loading: Especially dangerous in diabetic ketoacidosis management
• Renal artery stenosis: Triggers secondary hyperaldosteronism
• Hypokalemic familial periodic paralysis: Rare; see genetics section above

Neuromuscular Manifestations

Cardiac Manifestations and Electrocardiographic Findings

• U waves (small positive deflection after the T wave, 0.5–1 mm) are the earliest sign and highly specific for hypokalemia, though they may also occur with bradycardia or hypothermia
• T wave flattening or inversion (particularly in precordial leads V2–V4)
• ST segment depression ("sagging" appearance)
• QT prolongation (measured from Q wave to end of T wave)
• QU interval prolongation (from Q wave to end of U wave; may exceed 600 ms)
• Peaked P waves and PR interval prolongation (less specific)

Metabolic Derangements

Step 1 — confirm the value and screen for immediate danger

• Repeat serum potassium with a non-hemolyzed, promptly processed specimen. Pseudohypokalemia occurs when a sample from a patient with marked leukocytosis (acute leukemia) sits at room temperature and blasts take up potassium — the clue is a normal ECG in a patient with a reportedly critical value.
• 12-lead ECG plus telemetry in any patient with K <3.0 mEq/L, digoxin use, or structural heart disease. Look for U waves, T-wave flattening, ST depression, and QU prolongation.
• Serum magnesium is mandatory. Hypokalemia that will not correct despite adequate repletion is hypomagnesemic until proven otherwise.
• Basic metabolic panel and acid–base assessment (bicarbonate ± venous blood gas), plus glucose, creatinine, and calcium.

Step 2 — separate renal from extrarenal loss

• Spot urine potassium-to-creatinine ratio is the practical first test: a low ratio (roughly <13 mEq/g creatinine) indicates appropriate renal conservation and points to GI loss, poor intake, or transcellular shift; a higher ratio indicates renal potassium wasting. A 24-hour urine potassium above about 25–30 mEq/day carries the same meaning.
• The transtubular potassium gradient (TTKG) appears in older question banks but has been largely abandoned because its assumptions about medullary urea handling do not hold; do not choose it as the best next test.

Step 3 — branch on blood pressure and acid–base status

• Hypertension + metabolic alkalosis + renal wasting: screen for primary aldosteronism with a plasma aldosterone-to-renin ratio, as recommended by the Endocrine Society clinical practice guideline on primary aldosteronism, with confirmatory sodium/saline loading, then adrenal CT and adrenal vein sampling to determine lateralization. Suppressed renin and suppressed aldosterone suggests licorice, exogenous mineralocorticoid, or apparent mineralocorticoid excess.
• Normotensive + metabolic alkalosis: use urine chloride — low urine chloride indicates vomiting or remote diuretic use; high urine chloride indicates active diuretic use (send a urine diuretic screen), Bartter, or Gitelman syndrome. Gitelman is distinguished by hypomagnesemia with hypocalciuria.
• Metabolic acidosis with renal wasting: type 1 or type 2 RTA; check urine pH and the urine anion gap.
• Normal acid–base with abrupt onset: suspect transcellular shift — insulin, β2-agonists, thyrotoxic or familial periodic paralysis.

Immediate stabilization (K <2.5 mEq/L, ECG changes, arrhythmia, paralysis, or digoxin use)

• Continuous cardiac monitoring and IV potassium chloride. Peripheral infusion is generally limited to about 10 mEq/hour because of pain and phlebitis; higher rates require a central line with continuous telemetry. Potassium is never given as an IV push — bolus potassium causes asystole.
• Use saline, not dextrose, as the carrier fluid. Dextrose triggers endogenous insulin release and drives potassium intracellularly, transiently worsening the hypokalemia.
• IV magnesium sulfate if magnesium is low or the patient has torsades de pointes; per AHA ACLS guidance, magnesium is given for torsades regardless of the measured magnesium level. Magnesium repletion removes the block on ROMK-mediated potassium secretion and is required before hypokalemia will correct.

First-line repletion for mild-to-moderate deficits

• Oral potassium chloride (extended-release tablets or liquid) is preferred when the patient can take enteral medication; it is safer and self-limiting. Expect roughly a 200–400 mEq total body deficit for each 1 mEq/L fall in serum potassium, so repletion is iterative with serial levels.
• Salt selection follows the acid–base picture: potassium chloride for chloride-depletion alkalosis (vomiting, diuretics); potassium bicarbonate or citrate for RTA and chronic diarrhea; potassium phosphate when hypophosphatemia coexists, as in diabetic ketoacidosis.

Escalation and definitive management

• Potassium-sparing agents: aldosterone antagonists (spironolactone, eplerenone) for primary or secondary hyperaldosteronism, Bartter and Gitelman syndromes, and diuretic-induced losses; ENaC blockers (amiloride, triamterene) for amphotericin B toxicity, Liddle syndrome, and licorice-related mineralocorticoid excess. The ACC/AHA heart failure guideline already positions an MRA within guideline-directed therapy for HFrEF, where it doubles as potassium-sparing.
• Laparoscopic adrenalectomy is curative for a lateralizing unilateral aldosterone-producing adenoma; bilateral hyperplasia is managed medically with an MRA (Endocrine Society).
• Diabetic ketoacidosis: the ADA Standards of Care direct withholding insulin and repleting potassium first when the serum potassium is low, because insulin will otherwise precipitate life-threatening hypokalemia.

Avoid

• Aggressive repletion in periodic paralysis (including thyrotoxic periodic paralysis) — the potassium is shifted, not lost, and rebound hyperkalemia follows; give small doses and, for thyrotoxic periodic paralysis, a nonselective beta blocker such as propranolol.
• β2-agonists, dextrose-containing fluids, and potassium-sparing diuretics in advanced renal impairment.

Cardiac — emergencies

• Ventricular fibrillation and pulseless ventricular tachycardia: the shockable arrest rhythms. Hypokalemia prolongs repolarization and creates dispersion of refractoriness, permitting re-entry. Signaled by escalating ventricular ectopy and QU prolongation on telemetry; treat with immediate defibrillation and correct potassium and magnesium.
• Torsades de pointes: polymorphic VT on a prolonged QT background, especially with concurrent hypomagnesemia, hypocalcemia, or QT-prolonging drugs (sotalol, amiodarone, methadone). IV magnesium sulfate is the immediate therapy.
• Digoxin toxicity: hypokalemia reduces competition at the Na+/K+-ATPase binding site, so digoxin binds more avidly at any given level. The finding is bidirectional ventricular tachycardia or atrial tachycardia with block in a patient with a "therapeutic" digoxin concentration — a true emergency.

Neuromuscular

• Rhabdomyolysis: severe hypokalemia blunts exercise-induced vasodilation and causes ischemic myonecrosis. Signaled by markedly elevated creatine kinase, myoglobinuria, and a urine dipstick positive for blood without red cells on microscopy; may progress to AKI.
• Respiratory muscle weakness and diaphragmatic failure: an emergency; rising PaCO2 or falling vital capacity mandates airway support.
• Paralytic ileus: smooth muscle hypoexcitability producing distension, absent bowel sounds, and vomiting that worsens the potassium loss.

Renal and metabolic

• Hypokalemic nephropathy: chronic depletion downregulates aquaporin-2, producing a nephrogenic diabetes insipidus picture with polyuria and polydipsia; prolonged deficiency causes proximal tubular vacuolization and interstitial fibrosis.
• Increased renal ammoniagenesis: precipitates or worsens hepatic encephalopathy in cirrhosis — a key reason to replete potassium aggressively in that population.
• Impaired insulin secretion and worsened blood pressure, since potassium is required for beta-cell depolarization-coupled insulin release.

Complications of treatment

• Rebound hyperkalemia after repletion in transcellular-shift states (periodic paralysis, treated DKA); signaled by peaked T waves.
• Infusion-site phlebitis, pain, and extravasation necrosis from concentrated peripheral potassium chloride.
• GI mucosal ulceration and stricture from wax-matrix oral potassium tablets, particularly with delayed transit.
• Hyperkalemia and, with spironolactone, antiandrogenic gynecomastia — mitigated by switching to eplerenone.

• Refractory hypokalemia = check magnesium. Hypomagnesemia releases inhibition of the ROMK channel, so potassium is secreted as fast as it is replaced. The single best next step in a patient whose potassium will not rise despite repletion is to measure and replete magnesium — not to give more potassium.
• U waves are the classic ECG buzzword; the dangerous combination is hypokalemia plus a QT-prolonging drug, yielding torsades de pointes, treated with IV magnesium sulfate per AHA ACLS regardless of the magnesium level. The shockable arrest rhythms remain ventricular fibrillation and pulseless VT.
• Digoxin plus hypokalemia is the association examiners test most. Low potassium unmasks toxicity at a "normal" drug level; bidirectional ventricular tachycardia is the giveaway.
• DKA: check potassium before starting insulin. The ADA Standards of Care direct holding insulin and repleting potassium first when potassium is low, since insulin plus fluid resuscitation will drive it further down.
• Hypertension + hypokalemia + metabolic alkalosis → primary aldosteronism; the next step is a plasma aldosterone-to-renin ratio (Endocrine Society), then confirmatory sodium loading, CT, and adrenal vein sampling before any adrenalectomy.
• Urine chloride sorts out the normotensive alkalotic patient: low in vomiting or remote diuretic use, high with active diuretics, Bartter, or Gitelman. Gitelman = hypocalciuria (thiazide-like); Bartter = hypercalciuria (loop-like). Licorice and 11β-HSD inhibition mimic aldosterone excess with low renin and low aldosterone.
• Common distractors: giving potassium in a dextrose-containing fluid (stimulates insulin and worsens hypokalemia); IV potassium push (causes asystole); aggressive repletion in periodic paralysis (causes rebound hyperkalemia — the potassium is shifted, not lost); and choosing the transtubular potassium gradient, which has been abandoned as an unreliable calculation.